Alliance A042302 - Clinical Trial
Email to Participate
terri.lucas@duke.edu
Who Can Participate in the Study?
Age Group
Adults
Study Details
Full Title
Protocol A042302, Phase III Evaluation of Fixed Duration Zanubrutinib plus Sonrotoclax-Based Therapy Compared to Continuous Zanubrutinib in Previously Untreated Older Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Principal Investigator
Danielle M. Brander, MD
Hematologic Oncologist
Protocol Number
IRB:
PRO00120149
NCT:
NCT07321652
Phase
Phase III
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Email terri.lucas@duke.edu